Remission during sunitinib (a multikinase inhibitor and antiangiogenic drug) treatment correlates with appearance of macrocytosis. There are some suggestions that bevacizumab, an antiangiogenic drug, may result in macrocytosis as well. No available published data on the influence of bevacizumab on macrocytosis has been so far. This paper attempts to answer the question: does bevacizumab induce macrocytosis being a predictor of the response? Moreover, treatment of solid tumors and non-cancerous diseases is discussed in the second part of this paper.